Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biosyent Inc BIOYF


Primary Symbol: V.RX

Healthcare
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing... see more

Recent & Breaking News (TSXV:RX)

BioSyent Releases Results for Fourth Quarter and Full Year 2019

GlobeNewswire March 18, 2020

BIOSYENT SCHEDULES Q4 AND FULL YEAR 2019 EARNINGS RELEASE FOR MARCH 18, 2020

GlobeNewswire March 11, 2020

BioSyent Announces Adoption of Restricted Share Unit Plan

GlobeNewswire March 6, 2020

BioSyent Announces Renewal of Normal Course Issuer Bid

GlobeNewswire December 11, 2019

BioSyent Signs Exclusive Agreement for Pain Management Products

GlobeNewswire November 25, 2019

BioSyent Releases Results for Third Quarter and First Nine Months of 2019

GlobeNewswire November 20, 2019

BioSyent Schedules Q3 and YTD 2019 Earnings Release for November 20, 2019

GlobeNewswire November 12, 2019

BioSyent Named to the Growth 500 Ranking of Canada's Fastest-Growing Companies for Seventh Consecutive Year

GlobeNewswire September 12, 2019

BioSyent Releases Q2 and H1 2019 Results

GlobeNewswire August 23, 2019

BioSyent Schedules Q2 and H1 2019 Earnings Release for August 23, 2019

GlobeNewswire August 15, 2019

BioSyent Announces Withdrawal of Health Canada Submissions for Cardiovascular Products

GlobeNewswire June 26, 2019

BioSyent to Present at Raymond James Life Sciences and MedTech Conference

GlobeNewswire June 17, 2019

BioSyent Releases Results for Q1 2019

GlobeNewswire May 29, 2019

BioSyent Announces Health Canada Approval of New Women's Health Product

GlobeNewswire May 13, 2019

FeraMAX® Named #1 by Canadian Physicians and Pharmacists for Fourth Consecutive Year

GlobeNewswire May 2, 2019

BioSyent Announces Notice of Deficiency for Cardiovascular Products

GlobeNewswire March 22, 2019

BioSyent Releases Results for Fourth Quarter and Full Year 2018

GlobeNewswire March 20, 2019

BioSyent Schedules Q4 2018 Earnings Release for March 20, 2019

GlobeNewswire March 15, 2019

BioSyent Announces Normal Course Issuer Bid

GlobeNewswire December 4, 2018

BioSyent Releases Results for Third Quarter and First Nine Months of 2018

GlobeNewswire November 21, 2018